$ADAG News

Adagene to Participate in Two Upcoming Investor Conferences

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026

Adagene Looks Attractive With ADG126 And Validating Partnerships

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Guggenheim Maintains Buy on Adagene, Raises Price Target to $10

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Adagene shares are trading lower after the company announced that it priced a $70 million public offering of 18.7 million ADSs at $3.75 per ADS.

Adagene shares are trading lower after the company announced that it priced a $70 million public offering of 18.7 million ADSs at $3.75 per ADS.

Adagene Announces Results From Latest Data Cut From Phase 1b/2 Study Of Muzastotug In Patients With Advanced Microsatellite Stable Colorectal Cancer With No Liver Metastases

Adagene Prices $70.0M Public Offering Of 18,666,000 ADSs At $3.75 Per ADS With Participation From Janus Henderson, Deerfield And Invus

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon

Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk

Adagene to Participate in Two Upcoming Investor Conferences

Adagene Provides Business Update and 2026 Objectives

Adagene Announces Data Update From Ongoing Phase 1b/2 Study Of Muzastotug + Pembrolizumab In 3L+ MSS CRC Patients Remains On Track For Q1 2026